Evaluation of a Methadone Protocol for Severe Chronic Pain Management in Thai Patients: A Prospective Study

Phutsadee Pudchakan¹, Kritika Tanyasaensook¹, Pongparadee Chaudakshetrin², Penkae Ketumarn² and Chuthamanee Suthisisang³

¹Department of Pharmacy, Siriraj Hospital, Mahidol University, Bangkok, Thailand
²Department of Anesthesiology, Siriraj Hospital, Mahidol University, Bangkok, Thailand
³Department of Pharmacology, Mahidol University, Bangkok, Thailand

Abstract

Background: Methadone is a synthetic opioid that is clinically effective in chronic pain management. However, the use of methadone is very limited in Thailand because physicians are not familiar with its dosing and are concerned about risks relating to drug accumulation and cardiac arrhythmias.

Objective: The purpose of this study was to develop and implement a methadone protocol for patients with severe chronic pain in order to assure efficacy and safety of methadone.

Methods: The protocol was developed based on published clinical studies and guidelines. The validated protocol was implemented in 34 patients at the Pain Clinic, Siriraj Hospital, Bangkok, Thailand. During the study period, pain score, pain interference score, neuropathic pain score, severity of adverse effects, and QTc intervals were investigated over a 3 month period.

Results: The results obtained from 21 patients that completed the study showed a significant reduction in median pain intensity (p < 0.001) and other chronic pain interferences based on BPI-T (p < 0.001), excepted for the emotional score (p < 0.004) using methadone doses ranging from 2-30 mg daily. Neuropathic pain was also significantly reduced (p < 0.001). Common adverse effects were drowsiness (55.88%), constipation (35.29%), and nausea and/or vomiting (11.76%). Regarding ECG monitoring, seven patients without QTc prolongation at baseline developed QTc prolongation after methadone initiation. However, QTc interval greater than 500 msec or presentation of Torsades de Pointes were not found. No significant change in the mean QTc interval was observed after initiating methadone (p=0.951).

Conclusion: Administration of methadone according to the protocol described in this study was found to be effective and safe for severe chronic pain management. ECG monitoring and drug interaction screening in patient treatment plan is advised when prescribing methadone.

Keywords: Methadone; Chronic pain; Non-cancer pain; Cancer pain; QTc prolongation

Abbreviations

BPI-T = The Thai version of the Brief Pain Inventory
DN4 = Douleur Neuropathique en 4 questions
ECG = Electrocardiogram
HERG = Human ether-a-go-go-related gene
ITT = Intention-to-treat
NE = Norepinephrine
QTC intervals = corrected QT interval
TdP = Torsades de Pointes
5-HT = Serotonin

Introduction

Chronic pain is defined as pain that persists beyond normal tissue healing time or a duration longer than 3 months, as defined by the International Association for the Study of Pain (IASP) [1]. Symptoms include either continuous or intermittent pain that may be caused by tumor or multiple other etiologies. Chronic pain is a common problem in countries throughout the world, including Thailand [2-4]. The consequences of uncontrolled chronic pain result in not only physiological symptoms, but also psychiatric disorders that may lead to a severe and debilitating impact on daily life [2,5].

Methadone is a synthetic mu-opioid agonist. It has been proven as a clinically effective in chronic pain management [6,7]. Unlike morphine and fentanyl, methadone inhibits norepinephrine and serotonin re-uptake and exhibits non-competitive NMDA receptor blocking activity. These actions make methadone unique and can provide benefits in the management of neuropathic pain, opioid tolerance, and opioid-induced hyperalgesia [6,8,9]. Other positive aspects of methadone include no known active metabolites, long duration of analgesia, and low cost. Methadone, however, is not without associated cautions and concerns; one of which centers on a long and variable elimination half-life, which may lead to accumulation or delayed toxicity. Its metabolism involves cytochrome P450 (particularly CYP3A4, CYP2B6, and CYP2D6), which may result in the potential for drug interactions [10,11]. Moreover, QTc prolongation and/or Torsades de Pointes (TdP) have been reported during methadone therapy [12,13].

In current clinical practice, the use of methadone for pain management in Thailand has been very limited. This is due primarily to physician uncertainty regarding dosing and concerns relating to drug accumulation and cardiac arrhythmias.

As such, the aim of this study was to develop an evidence-based methadone protocol for severe chronic pain management and evaluate this protocol in Thai patients.

Methods

Phase I: Development of a methadone protocol: The development...
of this methadone protocol was based on an evidence-based review and our clinical experience. Publications relating to methadone dosing were retrieved from MEDLINE, EMBASE, and the Cochrane Database from their respective inceptions to October 2010. For the search, the word “methadone” was combined with the words “AND” or “OR” and then followed individually by each of the following words: “pain,” “chronic pain,” “non-cancer pain,” “cancer pain,” “guideline,” “expert opinion,” “consensus,” and “clinical practice.” These articles were then reviewed. Information considered germane to this study was extracted for use in the development of a methadone protocol. The developed protocol was then validated by pain specialists at Pain Clinic, Siriraj hospital.

Phase II: Testing the methadone protocol: An open-label prospective study was conducted at the Pain Clinic, Department of Anesthesiology, Siriraj Hospital, Mahidol University, from June 2011 to December 2013. This trial was approved by the Siriraj Institutional Review Board (SIRB). Calculation of sample size was based on 80% power with two-tailed test and 5% significance level to detect a two-point reduction in pain intensity using 11-point numerical pain rating scale [14]. Thirty-four out patients, aged 18 years or older, who suffered from severe chronic cancer or non-cancer pain, were eligible for this study. Only the patients who voluntarily signed consent of chronic opioid therapy were enrolled. Outpatients with baseline QTc interval > 500 msec, history of opioid addiction or structural heart diseases, and pregnancy or breastfeeding were excluded from the study. All adjuvant drugs were continued or adjusted by the pain specialist supervisors during the study.

The Thai version of the Brief Pain Inventory (BPI-T) [15] and Douleur Neuropathique en 4 questions (DN4) [16] were used for pain and neuropathic pain assessment, respectively. The intensity of opioid-related adverse events, including drowsiness (sedation score) and nausea and/or vomiting were assessed by the patient using a scale from 0 to 3 (0 = “not at all” or “awake”, 1 = “slightly” or “slightly drowsy”, 2 = “a lot” or “frequently drowsy”, 3 = “awful” or “somnolence”). Constipation symptoms were rated, as follows: 0 = 1-2 days per one passage, 1 = 3-4 days per one passage, 2 = 4-6 days per one passage, 3 = rectal measures [17]. Other side effects reported by patients during the study were also recorded. Moreover, a resting 12-lead ECG was used to determine QTc interval, which was corrected by heart rate using Bazett’s formula [18]. QTc prolongation was defined as >430 msec in men and >450 msec in women. If QTc interval is above 500 msec, it is considered to be a clinically significant prolongation [19,20]. Risk factors of QTc prolongation were also identified.

Methadone protocol

The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hour. In patients who required opioid rotation, the conversion ratios of morphine to methadone were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine, respectively. Switching methods was a stop-and-go or rapid switching. Breakthrough pain will be managed by morphine syrup as needed. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which therefore, was switched to be morphine syrup in the ratio of 1:4. The upward or downward titration should be 20-30% of initial daily dose of methadone for methadone solution. If methadone tablet was selected to be rescue drug, dose adjustments would be 2.5 mg each time depending on pain intensity and adverse effects. All adjuvant drugs and supportive medications which relieved constipation or nausea/ vomiting had been continued during the study. The developed protocol was shown in Table 1. Moreover, ECG monitoring and drug interactions screening between methadone and currently prescribed drugs, particularly CYP 3A4 and CYP 2D6 inhibitors, were checked before prescribing methadone.

Data collection

All patients underwent clinical assessment at baseline (W0), 2 weeks (W2), 4 weeks (W4), 8 weeks (W8), and 12 weeks (W12) after methadone initiation. The following data were gathered and recorded: age; gender; underlying disease; duration of pain; primary tumor site; type of pain; pre-switching analgesic doses; daily methadone dose; number of rescue doses in a 24-hour period; pain score; pain interference scores; intensity of adverse effects; QTc interval; and risk factor of QTc prolongation.

Statistical analysis

Data were analyzed using descriptive and frequency analysis. The Shapiro-Wilk test was used to test normality of interval data. For data normality, a repeated measures analysis of variance (ANOVA) was used to analyze the differences between group means. The Friedman test was used to detect and evaluate data deviations across multiple test attempts. The Wilcoxon signed-rank test was used for comparing two related samples of non-parametric data. Statistical significance was set at p < 0.05, with a two-sided test. The program used for analysis was SPSS version 18.0 (SPSS, Inc., IBM, Armonk, NY, USA).

Results

In a search of medical databases for developing methadone protocol, 3,629 articles were identified and retrieved. Some articles were excluded because they were either duplicated or they were not translated into English. Of 3,629 articles, 2,641 met the eligibility criteria for screening. Of those, 15 articles [17,21-34] were identified that provide useful information regarding administration of methadone for pain management. The methadone protocol that we developed is shown in Table 1.

Patient characteristics

Thirty four eligible patients were enrolled for protocol testing. A total of 13 patients dropped out of the study for a variety of reasons and at differing time points in the study. At W12, 12 patients with cancer pain and 9 patients with non-cancer pain had completed the study, as shown in Figure 1.

Demographic data of the 34 initially recruited patients are summarized in Table 2. Mean duration of pain was 12 months (range: 6-48). In the rotation group, the main reason for switching from oral morphine to oral methadone was poor pain control, despite escalating morphine doses. No participant used oral methadone as an alternative to transdermal fentanyl.

Of 23 patients who were diagnosed as cancer, 12 had metastatic stages, 7 had locally advanced cancer or recurrent stages, and 4 had unidentified stages. The top 3 primary tumor sites were: head and neck (43.46%), breast cancer (8%) and lung cancer (8%)

Methadone dosage

Methadone was initiated and adjusted, according to the developed protocol. In 26 opioid-naïve patients, average initial methadone dose was 7.63 mg daily (range: 4-10 mg). There were 15 patients (57.69%) that did not require a change in their methadone dosage throughout the study. The remaining 11 patients (42.31%) required dose adjustment at least once due to uncontrolled pain and/or intolerant side effects. The most notable intolerant side effect during the follow-up periods was drowsiness. The average dose difference that was increased from baseline was 67.71%. The highest methadone dose for pain control with
Screening before starting methadone:
- Inform patients about arrhythmia risk and clinical signs/symptoms of QTc prolongation
- Baseline ECG monitoring must be performed for all patients
- Methadone should not be prescribed in patients with QTc interval over 500 msec or in patients with history or presentation of structural heart disease (35)
- Screen for drug interaction, particularly for CYP 3A4, CYP 2B6 and CYP 2D6 inducers/inhibitors (10,11). (Notification of the interaction and suggestions regarding dose adjustment are communicated to physicians)

Starting methadone dose:
- Opioid-naive: Adult – 2.5-5 mg q 8-12 hr (21)
- Opioid rotation: Calculated methadone dose is divided into every 8-12 hr; initial dose should not exceed 30 to 40 mg daily (21)

| Conversion ratio |
|------------------|
| Oral MO:oral MET (27) | 4:1 |
| MO <90 mg | 8:1 |
| MO 90-300 mg | 12:1 |
| MO >300 mg | 20:1 |
| FEN patch/iv: oral MET (32) |

Notes: Elderly patients with renal impairment or hepatic insufficiency should be given less frequent dosing, according to clinical conditions (36); no supplemental dose is required after dialysis (37)

Breakthrough pain medications for severe pain:
- 10-15% of total daily dose of methadone, which was switched for morphine syrup at a ratio of 1:4 (22,26,30)

Evaluation after starting methadone:
- The first visit should take place 2 weeks after methadone initiation
- Upward or downward titration should not occur more frequently than once weekly by 20-30% (for 1 mg/ml methadone solution) or increased/decreased 2.5 mg (half of a 5 mg tablet) of total daily dose (22)
- If the QTc interval is >500 msec, the methadone dose should be reduced or substituted with other strong opioids (35)

Table 1: Developed methadone protocol by evidence-based review.

\[ \text{Conversion ratio} \]
\[
\begin{array}{|c|c|}
\hline
\text{Conversion ratio} & \text{MO: oral MET} \\
\hline
\text{MO <90 mg} & 4:1 \\
\text{MO 90-300 mg} & 8:1 \\
\text{MO >300 mg} & 12:1 \\
\text{FEN patch/iv: oral MET} & 20:1 \\
\hline
\end{array}
\]

Enrollment

Assessed for eligible (n=34)
- Excluded (n=4)
  - Not meeting inclusion criteria (n=2)
  - Declined to participate (n=2)

Intervention

Methadone initiation (n=34)

Follow-up

Discontinued methadone (n=13)
- Lost to follow-up (n=6)
- Intolerant adverse events (n=3)
- Death (n=2)
- Changed the medication due to uncontrolled pain (n=1)
- Refused to perform ECG (n=1)

Analysis

Analyzed (n=21)

Figure 1: Thirty four eligible patients were enrolled for protocol testing.

...
Changes in QTc interval

Four patients (19.05%) presented with QTc prolongation at baseline monitoring. However, after long-term follow-up, the QTc interval in these patients showed a decreasing trend. From 17 patients without QTc prolongation at baseline, 7 patients (33.33%) developed QTc prolongation during the study. Yet, no significant change in mean QTc interval was observed after initiating methadone (p = 0.916). QTc interval > 500 msec or conversion to TdP was not found at any point in the study, as shown in Table 6.

Many risk factors relating to QTc prolongation were observed in our patients. Unmodifiable risk factors of QTc prolongation were older age, female gender, and history of receiving cardiotoxic chemotherapy. Modifiable risk factors of QTc prolongation included hypokalemia, hypocalcaemia, and QTc prolonging drugs (amitriptyline and nortriptyline), which were detected. Hypokalemia and hypocalcaemia were corrected in all the cases.

Discussion

Chronic pain is one of many non-communicable diseases commonly found in Thailand. Methadone has several compelling pharmacologic properties, including the effective relief of somatic and neuropathic pain. However, the administration of methadone for pain management has been limited in Thailand due to dose-related uncertainties and concerns relating to risk of QTc prolongation. In response to these concerns, we endeavored to develop an evidence-based methadone protocol for pain management for use by clinicians who's familiar with its risks and dosing.

Although most of the established guidelines prefer to use methadone as an alternative to oral morphine, methadone is a valuable addition to the armamentarium of clinicians treating severe chronic pain, particularly when combined with neuropathic pain [38]. The recent EAPC guideline also suggested that methadone may be used as first- or second-line analgesic for severe cancer pain by a clinician who's familiar with its use [39]. The Cochrane reviewed 9 RCTs regarding the use of methadone in cancer pain concluded that methadone was similar to morphine in terms of the efficacy and tolerability, but its dose titration was generally lower compared to morphine [40]. For patients with chronic non-cancer pain, Chou et al. [21] and Cannadian practice guideline [41] suggested that opioids may be effective therapy and should be considered. However, Cochrane reviews of methadone in non-cancer pain was controversial [42]. In addition, three guidelines suggested that methadone may be benefit for naïve-opioid and rotation group with careful assessment and monitoring throughout treatment [21,43,44]. In our study, all naïve-opioid patients were enrolled due to severe pain with neuropathic component and expected to gain a benefit from methadone. The subgroup analysis results also demonstrated that the overall pain score in naïve-opioids group was significant improved (p < 0.001), patients who switched to methadone (p = 0.013), and patients with neuropathic pain (p < 0.001), as shown in Table 4. A comparative analysis of the overall pain score between cancer pain group and non-cancer pain groups demonstrated that there was no difference at W0, W2, W4, W8, but a significant reduction was found at W12 in cancer group (p = 0.041). For naïve-opioid patients and patients who switched to methadone, the overall pain score at W2, W4, W8, and W12 was not significantly different among groups. Focus on 12 patients with cancer pain, there were 7 naïve-opioid patients and 5 patients who switch morphine to methadone. No significant difference was observed. From 20 patients with no drowsiness at baseline, 12 patients reported slight drowsiness and 8 patients reported no drowsiness during the follow-up periods. Only one patient reported slight drowsiness from baseline and for the duration of the study. No patients had nausea and/or vomiting and received anti-emetics at baseline. During the study, one patient reported nausea and/or vomiting at W2, but these symptoms resolved and were not observed at W4, W8, and W12. Regarding constipation, 5 patients developed grade-1 constipation despite co-administration with stimulant laxative, as shown in Table 5.

Table 2: Demographic and clinical information of recruited patients.

| Characteristics               | Number of patients |
|-------------------------------|--------------------|
| Gender                        | Male : Female      |
| Age (years) Mean ± SD Range   | 50.44 ± 15.17 18-79|
| Classification of chronic pain (no. of patients) | 24 (67.65%) 11 (32.35%) |
| Type of patients (no. of patients) | 26 (76.47%) 8 (23.53%) |
| Type of pain (no. of patients) | Somatic pain 6 (17.65%) | Somatic with neuropathic pain 24 (70.57%) | Visceral with neuropathic pain 2 (5.89%) | Neuropathic pain 2 (5.89%) |
| Changes in QTc interval

From 20 patients with no drowsiness at baseline, 12 patients reported slight drowsiness and 8 patients reported no drowsiness during the follow-up periods. Only one patient reported slight drowsiness from baseline and for the duration of the study. No patients had nausea and/or vomiting and received anti-emetics at baseline. During the study, one patient reported nausea and/or vomiting at W2, but these symptoms resolved and were not observed at W4, W8, and W12. Regarding constipation, 5 patients developed grade-1 constipation despite co-administration with stimulant laxative, as shown in Table 5.
| Subgroup analysis | W0 (range) | W2 (range) | W4 (range) | W8 (range) | W12 (range) | P-value |
|------------------|------------|------------|------------|------------|-------------|---------|
| Patients with cancer pain (n=12) | 8 (7-10) | 2.5* (0-10) | 3* (0-10) | 4* (0-7) | 0.5* (0-6) | <0.001 |
| Patients with non-cancer pain (n=9) | 7 (7-10) | 5* (1-7) | 5* (2-7) | 5* (0-9) | 5* (0-10) | 0.013 |
| Naïve-opioid patients (n=16) | 7 (7-10) | 4.5* (0-8) | 4* (0-10) | 5* (0-9) | 3* (0-10) | <0.001 |
| Patients who switched to methadone (n=5) | 9.5 (7-10) | 2 (1-10) | 1* (0-6) | 5* (0-6) | 0* (0-6) | 0.013 |
| Patients with neuropathic pain (n=20) | 7.5 (7-10) | 4.5* (0-10) | 4* (0-10) | 5* (0-9) | 3* (0-10) | <0.001 |

Table 4: Overall pain score in each subgroup patient analyzed by the per protocol approach.
of example, Chou et al. recommended the safe starting dose for naïve opioid is 2.5 mg every 8 hours, however, it also suggested that there is insufficient evidence to recommend specific optimal starting doses. Bruea et al. chose 7.5 mg every 12 hr of methadone for naïve-opioid therapy. Moreover, we have revised the starting doses of methadone which have been used in Siriraj hospital. It was found that the starting dose in successful clinical naïve-opioid cases is 5 mg 8-12 hourly. Therefore, our recommendation that methadone dose be given 2.5 – 5 mg every 8 or 12 hours was based on clinical research findings and our clinical experience. Moreover, we do not recommend methadone syrup for breakthrough pain (reason: to avoid unintentional accumulated toxicities), even though some studies recommend methadone syrup for breakthrough pain [45,46].

In case of changing from oral morphine to oral methadone, the results obtained from systematic review showed that the conversion ratios widely ranged from 4:1 to 37:5:1 in pain treatment [47]. Some studies revealed that an initial fixed conversion ratio of 10:1 [25] and 5:1 [48] between morphine and methadone was effective and safe in patients with cancer pain. Mercadante et al. suggested that the successful conversion ratio depended on previous daily morphine dose which were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg, 90 to 300 mg, and greater than 300 mg of daily morphine, respectively. The other effective rotation formulas were Ripamonti et al and Ayonrinde et al. Regarding to incomplete cross-tolerance concept, the equi-analgesic dose of methadone is much lower in patients treated previously with very high doses of morphine. Therefore, the different dose ratios were reasonably applied to switch from oral morphine to methadone. In our study, we suggested the ratio of Mercadante et al. because it was proved to be effective in clinical setting. The switching method of Mercadante et al. which was stop-and-go method was similar to our study. While, Ripamonti et al and Ayonrinde et al used a different in switching method.

After starting the methadone regimen according to the developed protocol, our findings showed that median overall pain score from the protocol-recommended dose was found to effectively control pain. In addition, the calculation of methadone dose based on conversion ratio in this protocol provided effective guidance regarding methadone regimen in patients who switched from morphine to methadone. This methadone protocol was also found to effectively control somatic pain and neuropathic pain with acceptable tolerability.

Furthermore, the daily methadone dosages which elicited effective analgesia to improve pain, pain interferences, and neuropathic pain intensity in this study were relatively low (2-30 mg daily). These results were consistent with previous studies that used low doses of methadone (ranged from 2.5-30 mg daily) in management of severe non-cancer, cancer pain, and neuropathic pain [7,45,50]. This may be explained by the several analgesic mechanisms of methadone, including opioid agonist, NMDA antagonist, and monoamine reuptake inhibitor. Notably, stimulation of the NMDA receptor is a key mechanism in the development of chronic pain state, which was characteristic of our patients [51,52]. However, we were not able to rule out the effects of concomitant co-analgesics in pain score reduction, because some patients required increasing co-analgesic doses due to tumor progression.

Improvement in physical activities, emotions, sleep, and overall satisfaction scores are positive consequences of pain relief. Interestingly, methadone's ability to antagonize NMDA receptor and inhibit reuptake of monoamine appears to deliver benefit, due to the antidepressant-like effects [53-55]. Previous estimated values of serotonin (5-HT) reuptake inhibitor affinity (Ki) from animal studies showed that Ki values for R-methadone and racemic tramadol were 14.1 and 992 nM, respectively [56]; whereas, Ki values from cloned human receptors for amitriptyline and venlafaxine were 20 and 145 nM, respectively [57,58]. Regarding norepinephrine (NE) reuptake inhibitor affinities, Ki values from animal studies were 702 and 785 nM for R-methadone and racemic tramadol, respectively [56]; while, Ki values from the cloned human receptor of amitriptyline and venlafaxine were 50 and 1,420 nM, respectively [57,58]. For NMDA antagonism, Ki values from MK-801 binding assays, a binding site of methadone at the NMDA receptor, were 0.53, 0.61, 0.85, and 47 µM for ketamine, dextromethorphan, methadone and pethidine, respectively [39]. These properties also contributed to an improvement in somatic pain, neuropathic pain and emotional score in this study.

Concerning patient safety, acceptable levels of adverse effects like dizziness, constipation, nausea, and vomiting were reported during this study. These adverse effects were similar to those of other strong opioids accounting for µ receptor agonist [60]. Symptomatic treatments, including anti-emetics, laxatives, and/or methadone dose adjustment, effectively relieved these symptoms. No reduction in laxative requirement after switching from morphine to methadone was found during this study. This finding was inconsistent with a previous study that showed reduction in laxative doses after rotation to methadone [61]. Possible causes for increased constipation severity in our study may include poor intake, anticholinergic side effect of amitriptyline, and/or physical immobility of advanced cancer patients. One patient developed myoclonus while receiving oral methadone 10 mg daily, even though methadone is listed as being free of neuroexcitatory effects due to a lack of neurotoxic metabolites [62]. A possible mechanism for methadone-induced myoclonus may mediate through a non-opioid pathway, which is the serotonin reuptake blocking effect [62-65] revealed three cases of methadone-related myoclonus who received high methadone doses, ranging from 90-432 mg a day. It was reported that one patient developed myoclonus after receiving only 24 mg of methadone per day [66]. Myoclonus that is triggered by variation in methadone dose might be explained by differences in patient metabolic capacity and other aggravating factors, such as concomitant SSRI or SNRI administration and/or hepatic impairment.

Regarding cardiac safety, several previous experimental studies revealed that methadone could block the rapid component of the cardiac delayed rectifier potassium current (IKr) encoded by hERG (human ether-a-go-go-related gene), resulting in QTc prolongation [67,68]. From the group of patients without QTc prolongation at baseline, 7 (33.3%) patients developed QTc prolongation during the study. However, clinically significant change in QTc interval or TdP was not found in our study. This may be explained by the use of low-dose methadone, as compared with high methadone doses described in previous reports especially among patients with drug addiction (ranged 45-680 mg of methadone) [12,69]. Some studies have reported methadone related QTc prolongation ranging from 11% to 49.4% with low-dose methadone ranging from 5-80 mg during chronic pain.
management. There was also no report of methadone induced cardiac death or TdP among these patients [70-72].

Despite the fact that our protocol uses lower doses, we do recommend that a baseline 12-lead ECG is recorded and then repeated when risk factors occur, such as initiating unavoidable CYP 3A4 or 2D6 inhibitors or QTc prolonging drugs. Although not considered or evaluated in this study, genetic predisposition should also be considered as another contributing risk factor. Previous studies also reported that CYP2B6 [73] and CYP2C19 [74] polymorphisms, responsible for methadone metabolism for 12-32% and 2-14%, respectively [75], and hERG potassium channel polymorphisms [76,77] are involved in methadone-induced QTc prolongation. With respect to CYP2B6 polymorphisms, [73] demonstrated that CYP2B6 *6/*6 carriers had an increased risk of methadone-induced QTc prolongation, as compared with non-carriers (odds ratio = 4.5; 95% confidence interval = 1.2-17.7). This genotype presented in about 7.4%, 17%, and 7% of Caucasian [78], West African [79], and Thai [80] populations, respectively.

Our study had a high dropout rate of approximately 38% (13 patients). This high dropout rate reflected the complicated nature of advanced stage cancer patients: patients with poor prognosis and/or severe physical problems that discouraged follow-up. These impacted the power of the study that was decreased to 68%.

Conclusion

Methadone dosing based on the protocol presented in this study elicited pain management efficacy with acceptable tolerability, according to protocol-directed monitoring. Our findings indicate that low-dose methadone (2-30 mg daily) provides benefits that include improvements in pain, pain interferences, and neuropathic pain. However, monitoring of QTc prolongation and common adverse effects, such as constipation, drowsiness, and nausea and/or vomiting should be performed periodically during methadone usage.

Acknowledgements

The authors would like to gratefully acknowledge the team members of the Pain Management Unit, Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, Mahidol University for their support of and contribution to this study. The authors also wish to acknowledge and thank Ms. Pimrapat Tengtrakulcharoen for her valuable advice and guidance regarding statistical analysis and data management. Funding support for this study was provided by the Siriraj Routine to Research (R2R) Management Fund.

References

1. Merskey H (1986) Classification of chronic pain syndromes. Pain 3: 1-217.
2. van Hecke O, Torrance N, Smith BH (2013) Chronic pain epidemiology and its clinical relevance. Br J Anaesth 111: 13-18.
3. Johannes CB, Le TK, Zhou X, Johnston JA, Dworkin RH (2010) The prevalence of chronic pain in United States adults: results of an Internet-based survey. J Pain 11: 1230-1239.
4. Sakakibara T, Wang Z, Paholpik P, Kosuwon W, Oo M, et al. (2013) A comparison of chronic pain prevalence in Japan, Thailand, and Myanmar. Pain Physician 16: 603-608.
5. Anor BA, Hunkeler EM, Blasey CM, Lee J, Constantinou MJ, et al. (2006) Comorbid depression, chronic pain, and disability in primary care. Psychosom Med 68: 262-268.
6. Anghelescu DL, Faughnan LG, Hanks GM, Ward DA, Oakes LL (2011) Methadone use in children and young adults at a cancer center: a retrospective study. J Opioid Manag 7: 353-361.
7. Morley JS, Bridson J, Nash TP, Miles JB, White S, et al. (2003) Low-dose methadone has an analgesic effect in neuropathic pain: a double-blind randomized controlled crossover trial. Palliat Med 17: 576-587.
8. Inturrisi CE (2005) Pharmacology of methadone and its isomers. Minerva Anestesiol 71: 435-437.
9. Holman JR, Wala EP (2007) Characterization of the antinoceptive and pronociceptive effects of methadone in rats. Anesthesiology 106: 563-571.
10. McCance-Katz EF, Sullivan LE, Nallani S (2010) Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 19: 4-16.
11. Bruea E, Sweeney C (2002) Methadone use in cancer patients with pain: a review. J Palliat Med 5: 127-138.
12. Kao D, Bucher Bartelson B, Khatri V, Dart R, Mehler PS, et al. (2013) Trends in reporting methadone-associated cardiac arrhythmia, 1997-2011: an analysis of registry data. Ann Intern Med 158: 735-740.
13. Poluzzi E, Raschi E, Moretti U, De Ponti F (2009) Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Report System (AERS). Pharmacoepidemiol Drug Saf 18: 512-518.
14. Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94: 149-158.
15. Chaudakshetrin P (2009) Validation of the Thai Version of Brief Pain Inventory (BPI-T) in cancer patients. J Med Assoc Thai 92: 34-40.
16. Chaudakshetrin P, Peat reapchanish P, Chira-adaisi W, Tassananawips W, Leechavengvongs S, et al. (2007) Cross-cultural adaptation to the Thai language of the neuropathic pain diagnostic questionnaire (DN4). J Med Assoc Thai 90: 1860-1865.
17. Mercardante S, Porzio G, Ferrera P, Fulfarro F, Alesi F, et al. (2008) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 12: 1040-1046.
18. Bazzet HC (1920) An analysis of the time-relations of electrocardiograms. Heart 7: 353-367.
19. Crucciani RA (2008) Methadone: to ECG or not to ECG...That is still the question. J Pain Symptom Manage 36: 545-552.
20. van Noord C, Eigelsheim M, Stricker BH (2010) Drug- and non-drug-associated QT interval prolongation. Br J Clin Pharmacol 70: 16-23.
21. Chou R, Faciliulo GJ, Fine PG, Adler JA, Ballantyne JC, et al. (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 10: 113-130.
22. Fine PG, Portenoy RK (2009) Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 38: 418-425.
23. Säwe J, Hansen J, Gimmn C, Hårtvig P, Jakobsson PA, et al. (1981) Patient-controlled dose regimen of methadone for chronic cancer pain. Br J Clin Pharmacol Ed 26: 771-773.
24. de Conno F, Groff L, Brunelli C, Zecca E, Ventafredda V, et al. (1996) Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 14: 2836-2842.
25. Lawlor PG, Turner KS, Hansen J, Bruea ED (1998) Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82: 1167-1173.
26. Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, et al. (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 16: 3216-3221.
27. Mercardante S, Casuccio A, Calderone L (1999) Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 17: 3307-3312.
28. Mercardante S, Casuccio A, Fullaro F, Groff L, Boffi R, et al. (2001) Switching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective study. J Clin Oncol 19: 2988-2994.
29. Gagnon B, Altmarell A, Schreier G (2003) Methadone in the treatment of neuropathic pain. Pain Res Manag 8: 149-154.
30. Benitez-Rosario MA, Feria M, Salinas-Martin A, Martinez-Castillo LP, Martin-Ortega JJ (2004) Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain. Cancer 101: 2866-2873.
31. Bruea E, Palmer JL, Bosnjak S, Rico MA, Moyano J, et al. (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized,
32. Mercadante S, Ferrera P, Villari P, Casuccio A (2005) Rapid switching between transdermal fentanyl and methadone in cancer patients. J Clin Oncol 23: 5229-5234.

33. Altier N, Dion D, Boulanger A, Choinière M (2005) Management of chronic neuropathic pain with methadone: a review of 13 cases. Clin J Pain 21: 364-369.

34. Peng P, Tumber P, Stafford M, Gourlay D, Wong P, et al. (2008) Experience of methadone therapy in 100 consecutive chronic pain patients in a multidisciplinary pain center. Pain Med 9: 786-794.

35. Krantz MJ, Martin J, Stimmel M, Mehta D, Hailgney MC (2009) QTc interval screening in methadone treatment. Ann Intern Med 150: 387-396.

36. Pergolizzi J, Boger RH, Budd K, Dahan A, Erdine S, et al. (2008) Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract 8: 287-313.

37. Dean M (2004) Opioids in renal failure and dialysis patients. J Pain Symptom Manage 28: 497-504.

38. Ayonrinde OT, Bridge DT (2000) The rediscovery of methadone for cancer pain management. Med J Aust 173: 536-540.

39. Caraceni A, Hanks G, Dahan A, Erdine S, et al. (2009) Management of opioid therapy in cancer pain in adults: a review of the evidence. Pain Med 10: 512-522.

40. Nicholson AB (2007) Methadone for cancer pain. Cochrane Databse Syst Rev: CD003971.

41. Furlan AD, Reardon R, Welepler C; National Opioid Use Guideline Group (2010) Opioids for chronic noncancer pain: a new Canadian practice guideline. CMAJ 182: 923-930.

42. Haroutiunian S, McNicol ED, Lipman AG (2012) Methadone for chronic non-cancer pain in adults. Cochrane Database Syst Rev 11: CD008025.

43. The College of Physicians and Surgeons of British Columbia (2010) Recommendations for the use of methadone for pain.

44. Rofs RT, Johnson E, Williams NJ, Sundwall DN; Utah Department of Health (2010) Utah clinical guidelines on prescribing opioids for treatment of pain. J Pain Palliat Care Pharmacother 24: 219-235.

45. Parsons HA, de la Cruz M, Li Z, Calderon B, et al. (2010) Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 116: 520-528.

46. Rhondal W, Tremella F, Ledoux M, Ciais JF, Bruera E, et al. (2013) Methadone rotation for cancer patients with refractory pain in a palliative care unit: an observational study. J Palliat Med 16: 1382-1387.

47. Wescules DJ, Bain KT (2008) A systematic review of opioid conversion ratios used with methadone for the treatment of pain. Pain Med 9: 595-612.

48. Mercadante S, Ferrera P, Villari P, Casuccio A, Intravaia G, et al. (2009) Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 37: 632-641.

49. Farrar JT, Portenoy RK, Berlin JA, Kimman JL, Storn BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88: 287-294.

50. Salpeter SR, Buckley JS, Bruera E (2013) The use of very-low-dose methadone for palliative pain control and the prevention of opioid hyperalgesia. J Palliat Med 16: 616-622.

51. Petrenko AB, Yamakura T, Baba H, Shimoji K (2003) The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. Anesth Analg 97: 1108-1116.

52. Eide PK (2000) Wind-up and the NMDA receptor complex from a clinical perspective. Eur J Pain 4: 5-15.

53. Trullas R, Skolnick P (1990) Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 185: 1-10.

54. Yilmaz A, Schulz D, Aksoy A, Canteyli R (2002) Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 71: 341-344.

55. Rojas-Corrales MO, Berrocoso E, Gilbert-Rahola J, Micó JA (2002) Antidepressant-like effects of tramadol and other central analgesics with activity on monoamines reuptake, in helpless rats. Life Sci 72: 143-152.

56. Codd EE, Shank RP, Schupsky JJ, Raffa RB (1995) Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception. J Pharmacol Exp Ther 274: 1263-1270.

57. Gillman PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmaco 151: 737-748.

58. Vaishnavi SN, Nemeroff CB, Plot SJ, Rao SG, Kranzler J, et al. (2004) Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol Psychiatry 55: 320-322.

59. Ebert B, Wong EH, Kroogaard-Larsen P (1991) Identification of a novel NMDA receptor in rat cerebellum. Eur J Pharmacol 208: 49-52.

60. Shaoiva L (2005) The role of methadone in the treatment of moderate to severe cancer pain. Support Cancer Ther 2: 176-180.

61. Daenicke PJ, Bruera E (1999) Reduction in constipation and laxative requirements following opioid rotation to methadone: a report of four cases. J Pain Symptom Manage 18: 303-309.

62. Sarhill N, Davis MP, Walsh D, Nouneh C (2001) Methadone-induced myoclonus in advanced cancer. Am J Hosp Palliat Care 18: 51-53.

63. Han PK, Arnold MP, Bond G, Janson D, Abu-Elmagd K (2002) Myoclonus secondary to withdrawal from transdermal fentanyl: case report and literature review. J Pain Symptom Manage 23: 66-72.

64. Dvir Y, Smallwood P (2008) Serotonin syndrome: a complex but easily avoidable condition. Gen Hosp Psychiatry 30: 284-297.

65. Ito S, Liao S (2008) Myoclonus associated with high-dose parental methadone. J Palliat Med 11: 838-841.

66. Mercadante S (1995) Dantrolene treatment of opioid-induced myoclonus. Anesth Analg 81: 1307-1308.

67. Katchman AN, McGroary KA, Kilborn MJ, Komnick CA, Manfredi PL, et al. (2002) Influence of opioid agonists on cardiac human ether-a-go-go-related gene K(+) currents. J Pharmacol Exp Ther 303: 688-694.

68. Zünker BJ, Wos-Maganga M (2010) Comparison of the effects of methadone and heroin on human ether-a-go-go-related gene channels. Cardiovasc Toxicol 10: 161-165.

69. Krantz MJ, Lewkowitz L, Hays H, Woodruff MA, Robertson AD, et al. (2002) Torsade de points associated with very-high-dose methadone. Ann Intern Med 137: 501-504.

70. Grodofsky S, Edison E, Huang S, Speck RM, et al. (2015) The QTc effect of low-dose methadone for chronic pain: a prospective pilot study. Pain Med 16: 1112-1121.

71. Price LG, Wobeter B, Delate T, Kurz D, Shanahan R (2014) The QTc effect of low-dose methadone for chronic pain: a prospective study. Pain Med 15: 2257-2262.

72. Hult B, Park CH (2010) Retrospective analysis of low-dose methadone and QTc prolongation in chronic pain patients. Korean J Anesthesiol 58: 338-343.

73. Eap CB, Crettol S, Rouger JS, Schläpfer J, Grilo LS, et al. (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81: 719-728.

74. Wang SC, Ho IK, Tsou HH, Liu SW, Hsiao CF, et al. (2013) Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort. OMICS 17: 519-526.

75. Chang Y, Fang WB, Lin SN, Moody DE (2011) Stereoselective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic Clin Pharmacol Toxicol 108: 55-62.

76. He FZ, McLeod HL, Zhang W (2013) Current pharmacogenomic studies on hERG channel blockers and the QT interval prolongation of CYP2B6 slow metabolizers. Clin Pharmacol Ther 81: 719-728.

77. Anchersen K, Hansteen V, Gossop M, Clausen T, Waal H (2010) Opioid maintenance patients with QTc prolongation: congenital long QT syndrome mutation may be a contributing risk factor. Drug Alcohol Depend 112: 216-219.

78. Jacob RM, Johnstone EC, Neville MJ, Walton RT (2004) Identiﬁcation of CYP2B6 sequence variants by use of multiplex PCR with allele-speciﬁc genotyping. Clin Chem 50: 1372-1377.
79. Mehlotra RK, Ziats MN, Bockarie MJ, Zimmerman PA (2006) Prevalence of CYP2B6 alleles in malaria-endemic populations of West Africa and Papua New Guinea. S Eur J Clin Pharmacol 62: 267-275.

80. Sukasem C, Chamnanphon M, Koomdee N, Puangpetch A, Santon S, et al. (2013) High plasma efavirenz concentration and CYP2B6 polymorphisms in Thai HIV-1 infections. Drug Metab Pharmacokinet pp: 391-397.